Pipeline

We are developing a portfolio of first-in-class gene therapies based on our proprietary nano-delivery technology.

Program
Indication
Research
Preclinical
Phase 1
Phase 2
Phase 3
MG-001
Colon Cancer

Therapeutic Agent for Colorectal Cancer Patients with KRAS mutation

We developed a nanoliposome delivery system containing a guide RNA-cationic polymer complex that suppresses the expression of KRAS gene in colon cancer.

Cetuximab, which is currently used as a treatment for metastatic colorectal cancer, is effective only for patients with normal KRAS colorectal cancer. In addition, even if the KRAS mutation is not innate to patients, 60 to 80% of patients eventually develop the KRAS mutation due to continuous treatment of Cetuximab.

Moogene Medi's gene-editing nanoliposome delivery system has shown efficacy in treatment of KRAS mutant metastatic colorectal cancer by fundamentally suppressing the KRAS mutation at the nucleotide level.

 

Reference 

1 Gene editing particle system as a therapeutic approach for drug-resistant colorectal cancer. Nano Research 13, 1578-1585 (2020) (learn more)

2. " NANO-LIPOSOME CARRIER COMPOSITION CONTAINING HYBRID OF Cas9 PROTEIN AND GUIDE RNA"  USA, US20180193269A1 (learn more)

3. "Delivery carrier composition comprising nanoliposome encapsulating complex of Cas9 protein, guide RNA for repressing gene expression or KRAS gene and cationic polymer, or therapeutics comprising thereof for treating KRAS mutation colon cancer with anticancer drug resistance" Korea, KR 10-1796036 (learn more)

MG-002
Hair Loss

Therapeutic Agent for Androgenic Alopecia

We developed a nano liposome-microbubble to encapsulate and deliver Cas9-guide RNA complexes to suppress the expression of SRD5A2 gene as a topical treatment for hair loss.

Drugs currently used as hair loss treatment agent directly alter the systemic endocrine balance of patients, resulting in serious side effects such as loss of libido or erectile dysfunction; when the drug treatment is stopped, hair loss progresses again.

Using our nanoliposome-microbubble, we can topically target the genes of skin cells to suppress the fundamental causes of male pattern hair loss. Our results were presented at the 13th International Conference on Genomics (ICG-13), and our abstract “Topical Delivery of CRISPR/Cas9 Protein into Dermal Papilla Cells via Ultrasonic-activated Microbubble-nanoliposomal Particle” was awarded the top “Outstanding Poster Award”.

 

Reference 
1. Ultrasound-activated particles as CrISPR/Cas9 delivery system for androgenic alopecia therapy. Biomaterials. 232, 119736 (2020) (Learn more)
2. "Nanoliposome-microbubble assemblies encapsulating complex of Cas9 protein, guide RNA for repressing gene expression or SRD5A2 gene and cationic polymer, and composition comprising the same for improving or treating hair loss"  Korea KR 10-1870694B1 (Learn more)
MG-003
Diabetes Mellitus

Therapeutic Agent for Type 2 Diabetes

Type 2 diabetes is a disease in which insulin secretion function remains, but insulin resistance is relatively increased, and normal glycolysis is not achieved.

Currently, sitagliptin, a well-prescribed DPP4 inhibitor, is used, is used with side effects such as kidney toxicity and allergic reactions. The demand of its daily consumption also hinders compliance and quality of life, leading to suboptimal therapeutic outcomes.

Our novel gene editing system directly suppresses the genetic expression of DPP4, such that the body's insulin resistance is perpetually decreased, removing the need for lifetime drug consumption.

Reference

1. Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. J. Nanobiotechnology, 29;17(1): 19. (2019) (learn more)

2. "Nano-liposome carrier composition containing hybrid of Cas9 protein and guide RNA"  USA US10363217B2 (learn more)

3. "Composition comprising delivery carrier of nano-liposome having Cas9 protein and guide RNA" Korea KR101710026B1 (learn more) 

MG-004
Hair Loss

Topical Microbubble-Nanocarrier for Therapeutic Small Molecules (i.e. Finasteride)

We developed a topical microbubble  that can encapsulate drug for the treatment of hair loss, such as finasterid, Minoxidil, and Dutasteride.

Since oral administration such hair loss treatments leads to various systemic side effects, drug delivery through direct scalp application is most desirable. The limitation to topical application has been that the drug itself cannot penetrate well into hair follicle cells.

Our novel topical microbubble overcomes this limitation by using the cavitation effect of microbubbles to deliver drugs directly into follicle cells. These microbubble systems may minimize the side effects and enhance skin penetration efficiency of drugs for more effective treatment androgenic alopecia.

 

 

Reference 

1.  "Nanoliposome-microbubble assemblies encapsulating a durg for the treatment of androgenic alopecia, and composition comprising the same for improving or treating hair loss" Korea  KR 1020180069736 (learn more)

MG-005
Pancreatic Cancer

We are targeting the KRAS mutation in order to recover drug response to chemo-resistant tumors. Related patents can be accessed here. Research publications are under review and oncoming.

MG-006
Crohn's Disease

Under preliminary research. Research publications are under review and oncoming.